Experts offer advice on treating patients with belantamab mafodotin-based combinations in myeloma

In this discussion, the panel provides advice to community physicians on using belantamab mafodotin-based combinations in relapsed or refractory multiple myeloma, including dosing strategies and managing toxicities while maintaining efficacy. The panel features Dr. Saad Usmani, chief of myeloma service at Memorial Sloan Kettering Cancer Center, along with panelists Dr. Meletios A. Dimopoulos, professor and chairman of the department of clinical therapeutics at the National and Kapodistrian University of Athens School of Medicine, Dr. Hans Lee, director of myeloma research at the Sarah Cannon Research Institute, and Dr. Ajay Nooka, clinical member of the Cancer Prevention and Control Research Program at Winship Cancer Institute of Emory University. Given the complexities of patient access and preferences in global myeloma care, Dr. Lee stressed the need for personalized approaches to patient treatment. “One size doesn't fit all for our patient populations,” Dr. Lee said.